Progyny raises 2026 revenue outlook to $1.365B-$1.385B as it adds 1.3 million new covered lives

• "I'm pleased to report that Progyny had a strong quarter, resulting in record revenue and profitability for the third quarter as well as the continued generation of significant cash flow" (CEO & Director Peter Anevski), adding that the company is using cash flow "both to invest in the business for future growth and return value to our shareholders through a meaningful share repurchase activity."
• "We're exceptionally pleased with our results this selling season, which yielded a record 1.3 million new covered lives and over 85 new clients" (CEO & Director Anevski), and said the season also included "incremental 100,000 lives just since the last update of our expectations that we put out a month ago."
• "We are entering 2027 with our most diverse client base ever with no one area of the economy and no single client making an outsized contribution to our book" (CEO & Director Anevski). He also said new clients are launching "with an average of 2 to 3 Smart Cycles" and the company achieved "a near 100% attach rate for our pharmacy program" among new clients.
• "While the competitive environment remains active, we continue to see signs of some rationalization occurring in the market" (CEO & Director Anevski), adding, "we now see another significantly scaling back."
• "Under our most recent $200 million authorization, we purchased nearly 3 million shares during the third quarter for approximately $83 million" (Chief Financial Officer Mark Livingston), and said that in total the company "purchased more than 14 million shares overall since last November" and "reduced our overall shares outstanding by nearly 15% over the past year."

Outlook

• "We're pleased to raise the midpoint of our guidance for the year" (CFO Livingston), and guided full-year 2026 revenue to "$1.365 billion to $1.385 billion" and adjusted EBITDA to "$235 million to $240 million," with diluted EPS of "$1.30 and $1.35" and adjusted EPS of "$2.09 and $2.13" (CFO Livingston).
• For Q4 2026, management guided revenue to "$344.7 million to $364.7 million" and adjusted EBITDA to "$57.9 million to $62.9 million," with diluted EPS of "$0.36 and $0.41" and adjusted EPS of "$0.53 and $0.58" (CFO Livingston).
• On cadence of new client go-lives, "the majority of the over 85 clients and 1.3 million lives added in the most recent selling season are expected to go live in the first quarter of 2027," with "several hundred thousand, give or take" expected to launch midyear (CFO Livingston).
• Versus last quarter’s call, management moved from confidence in "adding 1 million or more new lives" (CEO & Director Anevski, Q2) to reporting "a record 1.3 million new covered lives" (CEO & Director Anevski, Q3), while maintaining that Progyny Select "was an immaterial contributor" in its first year (CEO & Director Anevski).

Financial Results

• "Revenue this quarter was above the midpoint of our guidance, reflecting a nearly 9% increase over 2025" (CFO Livingston).
• "Gross margin expanded by 130 basis points from the third quarter last year" (CFO Livingston), citing "a reduction in stock compensation expense" and "efficiencies we've continued to realize in the delivery of our care management services."
• "Adjusted EBITDA margin was modestly lower than a year ago" (CFO Livingston), while "adjusted EBITDA margin was 17.1%" on a trailing 12-month basis (CFO Livingston).
• "This quarter, we generated more than $56 million in operating cash flow" (CFO Livingston) and said DSO ended the quarter "at just under 66 days" (CFO Livingston).
• "As of September 30, we had $224 million in total working capital, which includes $196 million in cash, cash equivalents and marketable securities" and "no debt of any kind" (CFO Livingston).

Q&A

• Jailendra Singh, Truist: asked whether economics/utilization for a large public sector win (referencing CalPERS) differ from average; CEO & Director Anevski said, "from a margin profile perspective, we expect to be consistent with our business" and added, "we expect slightly lower utilization than our normal book of business for that population" based on underwriting.
• Jailendra Singh, Truist: asked whether 2027 could be a year of margin expansion as investments taper; CEO & Director Anevski said the company will set 2027 expectations later, but "the expectation that we have put out there already around us tapering back investments throughout 2027 still is the expectation."
• Scott Schoenhaus, KeyBanc: pressed on competitive conversions and very large employer opportunities; CEO & Director Anevski said, "yes, we saw conversion from those clients across our competitors" but added it "was not the biggest driver," and said there are "many large opportunities already" in the 2027 pipeline.
• Stanislav Berenshteyn, Wells Fargo: asked about Q4 visibility after Q3 seasonality; CFO Livingston said visibility was "very good for October as well as into November" and trends were returning to "normal healthy patterns."
• Constantine Davides, Citizens JMP: asked about upsell and product attach; CEO & Director Anevski said upsell commitments were "generally in line" and added, "we now expect about 96% of clients next year to have Rx" and "we'll have over 3 million lives with the expanded products starting in -- during 2027."
• Cameron Harbilas, Jefferies: asked what Progyny learned from the first selling season with Cigna; CEO & Director Anevski said, "I'm not sure that we learned anything significantly new" and cited joint work with "account executives" and integration.
• Cameron Harbilas, Jefferies: asked about eligibility file ingestion progress; CEO & Director Anevski said, "By year-end, we should have eligibility files for more than half of our lives."
• Sarah James, Cantor: asked how care-management savings are split between margin and client pricing; CFO Livingston said the practice has been ongoing "since inception" and that "we're mindful of where our clients are," while CEO & Director Anevski pointed to historical cost increases of "only up 1% to 2% a year" over a three-year period.
• David Larsen, BTIG: asked about long-term EBITDA margin goals and SG&A savings; CFO Livingston said, "We don't have a goal that we've put out to the marketplace," and linked margin/OpEx dynamics "to stock comp expense" rolling off, while expecting "incremental margins as we grow" after investment tapering.

Sentiment Analysis

• Analysts were slightly positive, emphasizing durability of demand and probing mechanics (public-sector utilization, Q4 visibility, competitive takeaways, and long-term margin framework), with repeated questions centered on selling-season sustainability and 2027 margin flow-through.
• Management tone was positive in prepared remarks and mostly confident in Q&A, using definitive framing such as "we're pleased to be in a position to raise the midpoint of our full year guidance" (CEO & Director Anevski) and reiterating, "we expect to be consistent with our business" on margins for large wins (CEO & Director Anevski).
• Compared with Q2’s heavier focus on explaining "slightly more pronounced" summer seasonality and visibility limits, Q3 featured fewer defensive clarifications and more emphasis on closed selling-season results and raised full-year guidance (CEO & Director Anevski; CFO Livingston).

Quarter-over-Quarter Comparison

• Q3 shifted the narrative from Q2’s expectation setting ("we are confident we will meet our annual target of adding 1 million or more new lives," CEO & Director Anevski, Q2) to reporting finalized outcomes: "record 1.3 million new covered lives and over 85 new clients" (CEO & Director Anevski, Q3).
• Full-year 2026 guidance language tightened upward in Q3 with "raise the midpoint" (CFO Livingston) versus Q2’s framing around seasonality and maintaining engagement assumptions through summer (CFO Livingston, Q2).
• Analyst focus moved from Q2’s repeated questioning on summer utilization/forecasting visibility to Q3’s deeper probing on competitive conversions, public-sector contract economics, Cigna channel execution, and 2027 margin trajectory.

Risks and Concerns

• "While the competitive environment remains active" (CEO & Director Anevski), management acknowledged ongoing competition even as it cited market "rationalization" and a competitor "significantly scaling back" (CEO & Director Anevski).
• Management highlighted macro cost pressure on employers: "It's also no secret that employers and members are dealing with some of the highest costs and trends in decades" (CEO & Director Anevski), positioning Progyny’s value proposition around "cost control" and outcomes.
• On utilization variability, management cautioned that "utilization has slight variations from time to time" and said it does not have visibility "that far out" for next year’s utilization (CEO & Director Anevski).

Final Takeaway

Progyny management characterized Q3 as a record quarter for revenue and profitability, paired with strong cash generation and material share repurchases. Leadership emphasized that the 2027 selling season outcome—1.3 million new covered lives and over 85 new clients with near-universal pharmacy attach—sets up a larger client and lives base once implementations complete, while maintaining that margins for large public-sector wins should be consistent with the business. Management raised the midpoint of full-year 2026 guidance and reiterated expectations that the elevated investment cycle begins to taper during 2027, with additional detail deferred until the year-end update.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.